RUTI®

BIOLOGICAL2 trials

Sponsors

Archivel Farma S.L.

Conditions

High-Risk Non-Muscle-Invasive Bladder CancerTuberculosis, Pulmonary

Phase 1

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

CompletedNCT03191578

Archivel Farma S.L.High-Risk Non-Muscle-Invasive Bladder Cancer

Start: 2017-06-16End: 2022-12-22Updated: 2023-07-14

Phase 2

Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)

CompletedNCT04919239

Archivel Farma S.L.Tuberculosis, Pulmonary

Start: 2021-09-22End: 2025-06-19Updated: 2025-12-10

Related Papers

A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.

2025-10-14

A heterologous prime-boost strategy using RUTI vaccine to improve the BCG response in non–muscle-invasive bladder cancer patients (RUTIVAC-1 trial).

Journal of Clinical Oncology2025-02-10